OncoSec became a public company in 2011.

OncoSec’s stock is traded on the NASDAQ Capital Market under the symbol ONCS.

Shares can be purchased through a licensed stockbroker or an online trading account. OncoSec does not have a direct stock purchase plan.

The CUSIP number of OncoSec’s common stock is 68234L207.

Not currently. OncoSec is a speculative growth stock. Dividends are normally paid from earnings and OncoSec does not currently generate earnings and profits.

Please visit www.oncosec.com or contact investor relations directly at investors@oncosec.com.

Visit www.oncosec.com to join our mailing list.

Visit our events page at www.oncosec.com/events and join our mailing list to be notified of upcoming presentations.

Management team profiles are available at www.oncosec.com/who-we-are.

OncoSec’s fiscal year ends July 31.

OncoSec’s headquarters are located at 3565 General Atomics Ct., San Diego, CA 92121. The main phone for this location is (858) 662-6732.

OncoSec is covered by the analysts listed below. For more information, please visit: http://ir.oncosec.com/analyst-coverage.

Mark Breidenbach - H.C. Wainwright
Jason Kolbert – Maxim Group
Rahul Jasuja – Noble Life Science Partners

Mayer Hoffman McCann P.C.

10616 Scripps Summit Court
San Diego, CA 92131

Morrison & Foerster LLP
12531 High Bluff Drive
San Diego, CA 92130

Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
P: 775-322-0626
www.natco.org
info@natco.org

858.662.6732
(858.ONCOSEC)
investors@oncosec.com